Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer of 2026 SAN DIEGO ...

New research based on real-world data largely aligns with the scientific literature, although one monoclonal antibody—dupilumab—stood out for its very low risk. Patients receiving monoclonal ...

ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) today announced that Health Canada has approved neffy ® 2 mg for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, ...

A new study by clinical researchers at Baylor College of Medicine and Texas Children’s Hospital offers insight on the primary triggers and management of childhood anaphylaxis. This severe, ...

The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer acetate (Copaxone, Glatopa), the agency announced on Wednesday. The warning ...

Researchers found that strong interactions between immune receptors promote antidrug antibody production, increasing the risk ...

Good news for those who suffer from severe allergic reactions: a nasal spray containing epinephrine rather than a needle can now treat those frightening moments. The treatment, called Neffy, was ...

Anaphylaxis is the most extreme form of severe allergic reactions which can be life threatening and requires emergency medical treatment. It can affect anyone of any age, sex, race and stature.

With new data and treatment strategies discussed at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual ...

Some of the celebration and excitement over the approval of the COVID vaccines has been dampened by recent reports of allergic complications. Twenty-one cases of confirmed anaphylaxis were identified ...